Archive ScienceWatch

 ScienceWatch

SPECIAL TOPICS

Diabetes - May 2009

Research Front Maps

Research front maps are diagrammatic representations of the core papers comprising each front. They are selected from the current Research Front set that are relevant to the featured special topic. The title for this Research Front Map is "DIPEPTIDYL PEPTIDASE-4 INHIBITION TREATMENT OF TYPE 2 DIABETES," containing 37 core papers. Source dates: 1999-February 28, 2009 (first bimonthly period 2009).

Each circle represents a highly cited paper whose bibliographic information is displayed when the user clicks on the circle. The solid lines between circles represent the strongest co-citation links for each paper (that is, indicating that the papers are frequently cited together); weaker links are indicated by dashed lines. Papers close to each other on the map are generally more highly co-cited. The most recent paper(s) are indicated in pink. Annotations may have been added to this map which represent the main research themes. These appear as labels attached to specific regions on the maps.

Note: For best results use the "landscape orientation" option when printing this page.
 

Ahren-2002 Villhauer-2003 Ahren-2004 Weber-2004 Ahren-2004 Kim-2005 Augeri-2005 Ahren-2005 Mari-2005 Lankas-2005 Ristic-2005 Herman-2005 Bergman-2006 Mu-2006 Pratley-2006 Raz-2006 Herman-2006 Rosenstock-2006 Aschner-2006 Charbonnel-2006 Scott-2007 Rosenstock-2007 Garber-2007 Nauck-2007 Rosenstock-2007 Brazg-2007 Pi-Sunyer-2007 Dejager-2007 Balas-2007 Vella-2007 Fonseca-2007 Goldstein-2007 Hermansen-2007 Schweizer-2007 Bolli-2008 Rosenstock-2008 Utzschneider-2008

DIPEPTIDYL PEPTIDASE-4 INHIBITION TREATMENT OF TYPE 2 DIABETES


 Core Papers 


Label: Ahren-2002
Title: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
Journal: DIABETES CARE, 25 (5): 869-875 MAY 2002
Citations: 218
Authors: Ahren, B;Simonsson, E;Larsson, H;Landin-Olsson, M;Torgeirsson, H;Jansson, PA;Sandqvist, M;Bavenholm, P;Efendic, S;Eriksson, JW;Dickinson, S;Holmes, D
Addresses:
Lund Univ, Dept Med, B11 BMC, S-22184 Lund, Sweden
Lund Univ, Dept Med, S-22184 Lund, Sweden
Lund Univ, Dept Med, Malmo, Sweden
Univ Gothenburg, Dept Med, Gothenburg, Sweden
Karolinska Hosp, Dept Endocrinol, S-10401 Stockholm, Sweden
Umea Univ, Dept Med, Umea, Sweden
Novartis, Basel, Switzerland


[Back to Map]     

Label: Ahren-2004
Title: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
Journal: J CLIN ENDOCRINOL METAB, 89 (5): 2078-2084 MAY 2004
Citations: 216
Authors: Ahren, B;Landin-Olsson, M;Jansson, PA;Svensson, M;Holmes, D;Schweizer, A
Addresses:
Lund Univ, Biomed Ctr B11, Dept Med, SE-21184 Lund, Sweden
Lund Univ, Biomed Ctr B11, Dept Med, SE-21184 Lund, Sweden
Univ Gothenburg, Dept Med, SE-41345 Gothenburg, Sweden
Umea Univ, Dept Med, SE-90185 Umea, Sweden
Novartis Pharmaceut, CH-4002 Basel, Switzerland


[Back to Map]     

Label: Ahren-2004
Title: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
Journal: DIABETES CARE, 27 (12): 2874-2880 DEC 2004
Citations: 195
Authors: Ahren, B;Gomis, R;Standl, E;Mills, D;Schweizer, A
Addresses:
Lund Univ, Dept Med, B11 BMC, SE-22184 Lund, Sweden
Lund Univ, Dept Med, SE-22184 Lund, Sweden
Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain
Diabet Res Inst, Munich, Germany
Novartis Pharma, Basel, Switzerland


[Back to Map]     

Label: Kim-2005
Title: (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-alpha]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Journal: J MED CHEM, 48 (1): 141-151 JAN 13 2005
Citations: 165
Authors: Kim, D;Wang, LP;Beconi, M;Eiermann, GJ;Fisher, MH;He, HB;Hickey, GJ;Kowalchick, JE;Leiting, B;Lyons, K;Marsilio, F;McCann, ME;Patel, RA;Petrov, A;Scapin, G;Patel, SB;Roy, RS;Wu, JK;Wyvratt, MJ;Zhang, BB;Zhu, L;Thornberry, NA;Weber, AE
Addresses:
Merck & Co Inc, Merck Res Labs, Mail Code RY800-C206,POB 2000, Rahway, NJ 07065 USA
Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA


[Back to Map]     

Label: Villhauer-2003
Title: 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
Journal: J MED CHEM, 46 (13): 2774-2789 JUN 19 2003
Citations: 163
Authors: Villhauer, EB;Brinkman, JA;Naderi, GB;Burkey, BF;Dunning, BE;Prasad, K;Mangold, BL;Russell, ME;Hughes, TE
Addresses:
Novartis Inst Biomed Res, Dept Chem, 1 Hlth Plaza, E Hanover, NJ 07936 USA
Novartis Inst Biomed Res, Dept Chem, E Hanover, NJ 07936 USA
Novartis Inst Biomed Res, Metab Dis Pharmacol Dept, E Hanover, NJ 07936 USA
Novartis Inst Biomed Res, Drug Metab & Pharmacokinet Dept, E Hanover, NJ 07936 USA


[Back to Map]     

Label: Lankas-2005
Title: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
Journal: DIABETES, 54 (10): 2988-2994 OCT 2005
Citations: 119
Authors: Lankas, GR;Leiting, B;Roy, RS;Eiermann, GJ;Beconi, MG;Biftu, T;Chan, CC;Edmondson, S;Feeney, WP;He, HB;Ippolito, DE;Kim, D;Lyons, KA;Ok, HO;Patel, RA;Petrov, AN;Pryor, KA;Qian, XX;Reigle, L;Woods, A;Wu, JK;Zaller, D;Zhang, XP;Zhu, L;Weber, AE;Thornberry, NA
Addresses:
Merck Res Labs, Dept Safety Assessment, R50G-2A-201,POB 200,E Lincoln Ave, Rahway, NJ USA
Merck Res Labs, Dept Safety Assessment, Rahway, NJ USA
Merck Res Labs, Dept Metab Disorders, Rahway, NJ USA
Merck Res Labs, Dept Pharmacol, Rahway, NJ USA
Merck Res Labs, Dept Drug Metab, Rahway, NJ USA
Merck Res Labs, Dept Med Chem, Rahway, NJ USA
Merck Res Labs, Dept Lab Anim Resources, Rahway, NJ USA
Merck Res Labs, Dept Immunol, Rahway, NJ USA
Merck Frosst Ctr Therapeut Res, Dorval, PQ, Canada


[Back to Map]     

Label: Charbonnel-2006
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Journal: DIABETES CARE, 29 (12): 2638-2643 DEC 2006
Citations: 116
Authors: Charbonnel, B;Karasik, A;Liu, J;Wu, M;Meininger, G;Sitagliptin Study 020 Grp
Addresses:
Merck Res Labs, Clin Res, 126 E Lincoln Ave,RY34A-254, Rahway, NJ 07065 USA
Merck Res Labs, Clin Res, Rahway, NJ 07065 USA
Ctr Hosp Univ Nantes, Nantes, France
Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel


[Back to Map]     

Label: Mari-2005
Title: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
Journal: J CLIN ENDOCRINOL METAB, 90 (8): 4888-4894 AUG 2005
Citations: 115
Authors: Mari, A;Sallas, WM;He, YL;Watson, C;Ligueros-Saylan, M;Dunning, BE;Deacon, CF;Holst, JJ;Foley, JE
Addresses:
Natl Res Ctr, Inst Biomed Engn, Corso Stati Uniti 4, I-35127 Padua, Italy
Natl Res Ctr, Inst Biomed Engn, I-35127 Padua, Italy
Nova Pharmaceut Corp, E Hanover, NJ 07936 USA
Novartis Inst Biomed Res, Cambridge, MA 02139 USA
PharmaWrite LLC, Princeton, NJ 08540 USA
Univ Copenhagen, Panum Inst, DK-2200 Copenhagen, Denmark


[Back to Map]     

Label: Ahren-2005
Title: Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
Journal: DIABETES CARE, 28 (8): 1936-1940 AUG 2005
Citations: 103
Authors: Ahren, B;Pacini, G;Foley, JE;Schweizer, A
Addresses:
Lund Univ, Dept Med, B11 BMC, SE-22184 Lund, Sweden
Lund Univ, Dept Med, SE-22184 Lund, Sweden
Italian Natl Res Council, Inst Biomed Engn, Metab Unit, Padua, Italy
Novartis Pharmaceut, E Hanover, NJ USA
Novartis Pharma, Basel, Switzerland


[Back to Map]     

Label: Aschner-2006
Title: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Journal: DIABETES CARE, 29 (12): 2632-2637 DEC 2006
Citations: 103
Authors: Aschner, P;Kipnes, MS;Lunceford, JK;Sanchez, M;Mickel, C;Williams-Herman, DE;Sitagliptin Study 021 Grp
Addresses:
Merck Res Labs, RY34-A232, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Colombian Diabet Assoc, Bogota, Colombia
Diabet & Glandular Dis Res Associates, San Antonio, TX USA


[Back to Map]     

Label: Herman-2005
Title: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Journal: CLIN PHARMACOL THER, 78 (6): 675-688 DEC 2005
Citations: 94
Authors: Herman, GA;Stevens, C;Van Dyck, K;Bergman, A;Yi, BM;De Smet, M;Snyder, E;Hilliard, D;Tanen, M;Tanaka, W;Wang, AQ;Zeng, W;Musson, D;Winchell, G;Davies, MJ;Ramael, S;Gottesdiener, KM;Wagner, JA
Addresses:
Merck Res Labs, Mail Code RY34-A536,POB 2000, Rahway, NJ 07065 USA
Merck & Co Inc, Whitehouse Stn, NJ USA
SGS Biopharma, Antwerp, Belgium


[Back to Map]     

Label: Raz-2006
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
Journal: DIABETOLOGIA, 49 (11): 2564-2571 NOV 2006
Citations: 93
Authors: Raz, I;Hanefeld, M;Xu, L;Caria, C;Williams-Herman, D;Khatami, H;Sitagliptin Study 023 Grp
Addresses:
Merck Res Labs, 126 E Lincoln Ave,RY34-A256, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Hadassah Univ Hosp, Ctr Diabet Res, IL-91120 Jerusalem, Israel
Tech Univ Dresden, Ctr Clin Studies, D-8027 Dresden, Germany


[Back to Map]     

Label: Rosenstock-2006
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Journal: CLIN THER, 28 (10): 1556-1568 OCT 2006
Citations: 90
Authors: Rosenstock, J;Brazg, R;Andryuk, PJ;Lu, KF;Stein, P;Sitagliptin Study 019 Grp
Addresses:
Merck Res Labs, 126 E Lincoln Ave,Mail Code RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Dallas Diabet & Endocrine Ctr, Dallas, TX USA
Rainier Clin Res Ctr, Renton, WA USA


[Back to Map]     

Label: Ristic-2005
Title: Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
Journal: DIABETES OBES METAB, 7 (6): 692-698 NOV 2005
Citations: 88
Authors: Ristic, S;Byiers, S;Foley, J;Holmes, D
Addresses:
Novartis Pharma AG, WSJ-202-2-14A, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland


[Back to Map]     

Label: Augeri-2005
Title: Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Journal: J MED CHEM, 48 (15): 5025-5037 JUL 28 2005
Citations: 87
Authors: Augeri, DJ;Robl, JA;Betebenner, DA;Magnin, DR;Khanna, A;Robertson, JG;Wang, AY;Simpkins, LM;Taunk, P;Huang, Q;Han, SP;Abboa-Offei, B;Cap, M;Xin, L;Tao, L;Tozzo, E;Welzel, GE;Egan, DM;Marcinkeviciene, J;Chang, SY;Biller, SA;Kirby, MS;Parker, RA;Hamann, LG
Addresses:
Lexicon Pharmaceut, 350 Carter Rd, Princeton, NJ 08540 USA
Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery Chem, Princeton, NJ 08543 USA
Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Metab Dis, Princeton, NJ 08543 USA
Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Pharmaceut Candidate Optimizat, Princeton, NJ 08543 USA
Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Exploratory Pharmaceut, Princeton, NJ 08543 USA
Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Chem Enzymol, Princeton, NJ 08543 USA


[Back to Map]     

Label: Weber-2004
Title: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes
Journal: J MED CHEM, 47 (17): 4135-4141 AUG 12 2004
Citations: 86
Authors: Weber, AE
Addresses:
Merck Res Labs, POB 2000, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA


[Back to Map]     

Label: Nauck-2007
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
Journal: DIABETES OBES METAB, 9 (2): 194-205 MAR 2007
Citations: 76
Authors: Nauck, MA;Meininger, G;Sheng, D;Terranella, L;Stein, PP;Sitagliptin Study 024 Grp
Addresses:
Merck Res Labs, 126 E Lincoln Ave,Mail Code RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Diabet Zentrum Bad Lauterberg Harz, Bad Lauterberg im Harz, Germany


[Back to Map]     

Label: Rosenstock-2007
Title: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Journal: DIABETES CARE, 30 (2): 217-223 FEB 2007
Citations: 73
Authors: Rosenstock, J;Mills, D;Baron, MA;Schweizer, A;Dejager, S
Addresses:
Dallas Diabet & Endsocrine Ctr Med City, 7777 Forest Ln,C-618, Dallas, TX 75230 USA
Dallas Diabet & Endsocrine Ctr Med City, Dallas, TX 75230 USA
Novartis Pharmaceut, E Hanover, NJ USA
Novartis Pharma AG, Basel, Switzerland


[Back to Map]     

Label: Pratley-2006
Title: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
Journal: HORMONE METAB RES, 38 (6): 423-428 JUN 2006
Citations: 66
Authors: Pratley, RE;Jauffret-Kamel, S;Galbreath, E;Holmes, D
Addresses:
Univ Vermont, Coll Med, Diabet & Metab Translat Med Unit, FAHC Arnold 3412,1 S Prospect St, Burlington, VT 05401 USA
Univ Vermont, Coll Med, Diabet & Metab Translat Med Unit, Burlington, VT 05401 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut, E Hanover, NJ USA


[Back to Map]     

Label: Herman-2006
Title: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Journal: J CLIN ENDOCRINOL METAB, 91 (11): 4612-4619 NOV 2006
Citations: 63
Authors: Herman, GA;Bergman, A;Stevens, C;Kotey, P;Yi, BM;Zhao, P;Dietrich, B;Golor, G;Schrodter, A;Keymeulen, B;Lasseter, KC;Kipnes, MS;Snyder, K;Hilliard, D;Tanen, M;Cilissen, C;De Smet, M;Lepeleire, I;Van Dyck, K;Wang, AQ;Zeng, W;Davies, MJ;Tanaka, W;Holst, JJ;Deacon, CF;Gottesdiener, KM;Wagner, JA
Addresses:
Merck Res Labs, RY34,A4031,126 E Lincoln Ave, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
3ClinResearch AG, D-16761 Berlin, Germany
Focus Clin Drug Dev GmbH, D-41460 Neuss, Germany
Free Univ Brussels, B-1050 Brussels, Belgium
Clin Pharmacol Associates, Miami, FL 33142 USA
Diabet & Glandular Dis Res Associates, San Antonio, TX 78229 USA
MSD Europe, B-1180 Brussels, Belgium
Univ Copenhagen, DK-2200 Copenhagen, Denmark


[Back to Map]     

Label: Bergman-2006
Title: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
Journal: CLIN THER, 28 (1): 55-72 JAN 2006
Citations: 60
Authors: Bergman, AJ;Stevens, C;Zhou, YY;Yi, BM;Laethem, M;De Smet, M;Snyder, K;Hilliard, D;Tanaka, W;Zeng, W;Tanen, M;Wang, AQ;Chen, L;Winchell, G;Davies, MJ;Ramael, S;Wagner, JA;Herman, GA
Addresses:
Merck Res Labs, RY34-A536,126 E Lincoln Ave, Rahway, NJ 07065 USA
Merck & Co Inc, Whitehouse Stn, NJ USA
SGS Biopharma, Antwerp, Belgium


[Back to Map]     

Label: Mu-2006
Title: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
Journal: DIABETES, 55 (6): 1695-1704 JUN 2006
Citations: 60
Authors: Mu, J;Woods, J;Zhou, YP;Roy, RS;Li, ZH;Zycband, E;Feng, Y;Zhu, L;Li, C;Howard, AD;Moller, DE;Thornberry, NA;Zhang, BB
Addresses:
Merck Res Labs, Dept Metab Disorders, RY80W K180,POB 2000, Rahway, NJ 07065 USA
Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA
Merck Res Labs, Dept Immunol & Inflammat, Rahway, NJ USA


[Back to Map]     

Label: Pi-Sunyer-2007
Title: Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
Journal: DIABETES RES CLIN PRACT, 76 (1): 132-138 APR 2007
Citations: 51
Authors: Pi-Sunyer, FX;Schweizer, A;Mills, D;Dejager, S
Addresses:
St Lukes Roosevelt Hosp, Dept Med, 1111 Amsterdam Ave,Room 1020, New York, NY 10025 USA
St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut Corp, E Hanover, NJ USA


[Back to Map]     

Label: Rosenstock-2007
Title: Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
Journal: DIABETES OBES METAB, 9 (2): 175-185 MAR 2007
Citations: 48
Authors: Rosenstock, J;Baron, MA;Camisasca, RP;Cressier, F;Couturier, A;Dejager, S
Addresses:
Novartis Pharmaceut Corp, 1 Hlth Plaza, E Hanover, NJ 07936 USA
Novartis Pharmaceut Corp, E Hanover, NJ 07936 USA
Dallas Diabet & Endocrine Ctr, Dallas, TX USA
Novartis Pharma AG, Basel, Switzerland


[Back to Map]     

Label: Fonseca-2007
Title: Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
Journal: DIABETOLOGIA, 50 (6): 1148-1155 JUN 2007
Citations: 46
Authors: Fonseca, V;Schweizer, A;Albrecht, D;Baron, MA;Chang, I;Dejager, S
Addresses:
Tulane Univ, Hlth Sci Ctr, Dept Endocrinol, 1430 Tulane Ave,SL53, New Orleans, LA 70112 USA
Tulane Univ, Hlth Sci Ctr, Dept Endocrinol, New Orleans, LA 70112 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut Corp, E Hanover, NJ USA


[Back to Map]     

Label: Scott-2007
Title: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
Journal: INT J CLIN PRACT, 61 (1): 171-180 JAN 2007
Citations: 42
Authors: Scott, R;Wu, M;Sanchez, M;Stein, P
Addresses:
Merck Res Labs, 126 E Lincoln Ave,RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Christchurch Sch Med, Christchurch, New Zealand


[Back to Map]     

Label: Garber-2007
Title: Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
Journal: DIABETES OBES METAB, 9 (2): 166-174 MAR 2007
Citations: 36
Authors: Garber, AJ;Schweizer, A;Baron, MA;Rochotte, E;Dejager, S
Addresses:
Baylor Coll Med, Div Endocrinol, 6550 Fannin St,Suite 1045, Houston, TX 77030 USA
Baylor Coll Med, Div Endocrinol, Houston, TX 77030 USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceut Corp, E Hanover, NJ USA


[Back to Map]     

Label: Goldstein-2007
Title: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Journal: DIABETES CARE, 30 (8): 1979-1987 AUG 2007
Citations: 36
Authors: Goldstein, BJ;Feinglos, MN;Lunceford, JK;Johnson, J;Williams-Herman, DE;Sitagliptin 036 Study Grp
Addresses:
Merck Res Labs, RY37-A232, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Jefferson Med Coll, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA USA
Duke Univ, Ctr Med, Div Endocrinol Metab & Nutr, Durham, NC USA


[Back to Map]     

Label: Dejager-2007
Title: Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
Journal: HORMONE METAB RES, 39 (3): 218-223 MAR 2007
Citations: 35
Authors: Dejager, S;Razac, S;Foley, JE;Schweizer, A
Addresses:
Novartis Pharmaceut Corp, 1 Hlth Plaza, E Hanover, NJ 07936 USA
Novartis Pharmaceut Corp, E Hanover, NJ 07936 USA
Novartis Pharma AG, Basel, Switzerland


[Back to Map]     

Label: Hermansen-2007
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
Journal: DIABETES OBES METAB, 9 (5): 733-745 SEP 2007
Citations: 31
Authors: Hermansen, K;Kipnes, M;Luo, E;Fanurik, D;Khatami, H;Stein, P;Sitagliptin Study 035 Grp
Addresses:
Merck Res Labs, 126 E Lincoln Ave,Mail Cde Ry34-A256, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
Diabetes & Glandular Labs, San Antonio, TX USA


[Back to Map]     

Label: Schweizer-2007
Title: Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes
Journal: DIABETIC MED, 24 (9): 955-961 SEP 2007
Citations: 31
Authors: Schweizer, A;Couturier, A;Foley, JE;Dejager, S
Addresses:
Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland
Novartis Pharma AG, CH-4002 Basel, Switzerland
Novartis Pharmaceut Corp, Basel, Switzerland
Novartis Pharmaceut Corp, E Hanover, NJ USA


[Back to Map]     

Label: Vella-2007
Title: Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes
Journal: DIABETES, 56 (5): 1475-1480 MAY 2007
Citations: 30
Authors: Vella, A;Bock, G;Giesler, PD;Burton, DB;Serra, DB;Saylan, ML;Dunning, BE;Foley, JE;Rizza, RA;Camilleri, M
Addresses:
Mayo Clin, Coll Med, Endocrine Res Unit, Div Endocrinol Diabet Metab & Nutr, 5 Jo 194,200 1st St SW, Rochester, MN 55905 USA
Mayo Clin, Coll Med, Endocrine Res Unit, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA
Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
Novartis Pharmaceut, E Hanover, NJ USA
PharmaWrite, Princeton, NJ USA


[Back to Map]     

Label: Brazg-2007
Title: Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes
Journal: DIABETES OBES METAB, 9 (2): 186-193 MAR 2007
Citations: 28
Authors: Brazg, R;Xu, L;Dalla Man, C;Cobelli, C;Thomas, K;Stein, PP
Addresses:
Merck Res Labs, 126 E Lincoln Ave,RY34-A220, Rahway, NJ 07065 USA
Merck Res Labs, Rahway, NJ 07065 USA
Rainier Clin Res Ctr, Renton, WA USA
Univ Padua, Dept Informat Engn, Padua, Italy


[Back to Map]     

Label: Balas-2007
Title: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
Journal: J CLIN ENDOCRINOL METAB, 92 (4): 1249-1255 APR 2007
Citations: 27
Authors: Balas, B;Baig, MR;Watson, C;Dunning, BE;Ligueros-Saylan, M;Wang, Y;He, YL;Darland, C;Holst, JJ;Deacon, CF;Cusi, K;Mari, A;Foley, JE;DeFronzo, RA
Addresses:
Univ Texas, Hlth Sci Ctr, Dept Med, Diabet Div, 7703 Floyd Curl Dr,MC 886, San Antonio, TX 78229 USA
Univ Texas, Hlth Sci Ctr, Dept Med, Diabet Div, San Antonio, TX 78229 USA
Novartis Inst Biomed Res, Cambridge, MA 02139 USA
PharmaWrite LLC, Princeton, NJ 08540 USA
Novartis Pharmaceut Corp, E Hanover, NJ 07054 USA
Univ Copenhagen, Panum Inst, DK-2400 Copenhagen, Denmark
CNR, Inst Biomed Engn, I-35127 Padua, Italy


[Back to Map]     

Label: Rosenstock-2008
Title: Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
Journal: DIABETES CARE, 31 (1): 30-35 JAN 2008
Citations: 10
Authors: Rosenstock, J;Holst, JJ;Foley, JE;Deacon, CF;Rendell, M;Rochotte, E;Landin-Olsson, M;Baron, MA
Addresses:
Nova Pharmaceut Corp, 1 Hlth Pl, E Hanover, NJ 07936 USA
Nova Pharmaceut Corp, E Hanover, NJ 07936 USA
Dallas Diabet & Endocrine Ctr, Dallas, TX USA
Creighton Diabet Ctr, Omaha, NE USA
Univ Hosp, Lund, Sweden
Univ Copenhagen, Panum Inst, Copenhagen, Denmark
Novarti Pharma AG, Basel, Switzerland


[Back to Map]     

Label: Bolli-2008
Title: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study
Journal: DIABETES OBES METAB, 10 (1): 82-90 JAN 2008
Citations: 9
Authors: Bolli, G;Dotta, F;Rochotte, E;Cohen, SE
Addresses:
Nova Pharmaceut Corp, 400 Technol Square, Cambridge, MA 02139 USA
Univ Perugia, Sect Internal Med Endocrinol & Metabol, Perugia, Italy
Univ Studi Siena, Policlin Le Scotte, Siena, Italy
Novartis Pharma AG, Clin Dev, Basel, Switzerland
Nova Pharmaceut Corp, Clin Dev, Cambridge, MA 02139 USA


[Back to Map]     

Label: Utzschneider-2008
Title: The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose
Journal: DIABETES CARE, 31 (1): 108-113 JAN 2008
Citations: 7
Authors: Utzschneider, KM;Tong, J;Montgomery, B;Udayasankar, J;Gerchman, F;Marcovina, SM;Watson, CE;Ligueros-Saylan, MA;Foley, JE;Holst, JJ;Deacon, CF;Kahn, SE
Addresses:
VA Puget Sound Hlth Care Syst, 1660 S Columbian Wy, Seattle, WA 98108 USA
VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA
Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
Univ Washington, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA
Novartis Inst Biomed Res, Cambridge, MA USA
Novartis Pharmaceut, E Hanover, NJ USA
Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen, Denmark


[Back to Map]

KEYWORDS: DIPEPTIDYL PEPTIDASE-4 INHIBITOR VILDAGLIPTIN IMPROVES BETA-CELL FUNCTION; TYPE 2 DIABETES FAILING THIAZOLIDINEDIONE MONOTHERAPY; TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED; TYPE 2 DIABETES INADEQUATELY CONTROLLED.
[6536: (2002-2008_6) (CHE-CLI: ST Diabetes)]



Special Topics : Diabetes : DIPEPTIDYL PEPTIDASE-4 INHIBITION TREATMENT OF TYPE 2 DIABETES - Diabetes